CN111138487A - Preparation method and application of tricyclohexyltin 1-naphthoate complex - Google Patents
Preparation method and application of tricyclohexyltin 1-naphthoate complex Download PDFInfo
- Publication number
- CN111138487A CN111138487A CN201911369692.6A CN201911369692A CN111138487A CN 111138487 A CN111138487 A CN 111138487A CN 201911369692 A CN201911369692 A CN 201911369692A CN 111138487 A CN111138487 A CN 111138487A
- Authority
- CN
- China
- Prior art keywords
- tricyclohexyltin
- complex
- naphthoate
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RIWNMYQWDKWOMT-UHFFFAOYSA-M tricyclohexylstannyl naphthalene-1-carboxylate Chemical compound C1(=CC=CC2=CC=CC=C12)C(=O)[O-].C1(CCCCC1)[Sn+](C1CCCCC1)C1CCCCC1 RIWNMYQWDKWOMT-UHFFFAOYSA-M 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 24
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 18
- WCMMILVIRZAPLE-UHFFFAOYSA-M cyhexatin Chemical compound C1CCCCC1[Sn](C1CCCCC1)(O)C1CCCCC1 WCMMILVIRZAPLE-UHFFFAOYSA-M 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
- 201000010881 cervical cancer Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 9
- 230000001093 anti-cancer Effects 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 9
- 238000000902 119Sn nuclear magnetic resonance spectroscopy Methods 0.000 claims description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000002329 infrared spectrum Methods 0.000 claims description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 229910052718 tin Inorganic materials 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- -1 tin carboxylate Chemical class 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003606 tin compounds Chemical class 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- ODOPKAJVFRHHGM-UHFFFAOYSA-N phenyltin Chemical class [Sn]C1=CC=CC=C1 ODOPKAJVFRHHGM-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001942 tin-119 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- HCHHOTHWTKVCLK-UHFFFAOYSA-M tricyclohexylstannyl naphthalene-2-carboxylate Chemical compound C1=C(C=CC2=CC=CC=C12)C(=O)[O-].C1(CCCCC1)[Sn+](C1CCCCC1)C1CCCCC1 HCHHOTHWTKVCLK-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2224—Compounds having one or more tin-oxygen linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a preparation method and application of a tricyclohexyltin 1-naphthoate complex, which is a complex with a structural formula (I)
Description
Technical Field
The invention relates to a tricyclohexyl tin 1-naphthoate complex, a preparation method thereof and application of the complex in preparing an anti-tumor medicament.
Background
The organic tin carboxylate has high bioactivity and wide application prospect in the fields of sterilization, insecticide, anti-cancer drug preparation and the like, so that research on synthesis, structure and bioactivity of organic tin carboxylate complexes is widely concerned by scientists. The existing research shows that the alkyl R in the organotin carboxylate is the main factor for determining the anticancer activity of the compound, for example, cyclohexyl, n-butyl and phenyl tin compounds have stronger anticancer activity, and ethyl has almost no anticancer activity, and the known organotin compounds generally have stronger toxicity, so the application is limited. Regulating the balance between toxicity and biological activity is an important direction of research. The functional activation of alkyl or ligand can greatly change the coordination mode of tin atom, and further influence the bioactivity of organic tin complex. Research shows that the toxicity of the organic tin compound is related to the relative molecular mass of the organic tin compound, the smaller the relative molecular mass is, the greater the toxicity is, and the larger the relative molecular mass of the large steric hindrance alkyl tin. Therefore, the novel large steric hindrance alkyl tin carboxylate complex is synthesized, and the structure and the biological activity of the complex are researched, so that the complex has important research significance.
Chinese patent CN 106188128B discloses the application of tricyclohexyltin 2-naphthoate in preparing medicine for treating lung cancer, breast cancer and liver cancer.
Chinese patent CN 103396437B discloses the application of tricyclohexylstannate in preparing medicine for treating cervical cancer, breast cancer, liver cancer, colon cancer and lung cancer.
Chinese patent CN 103087325B discloses the application of ferrocenyl tricyclohexylstannate complex in preparing medicine for treating liver cancer, nasopharyngeal carcinoma, breast cancer, colon cancer and lung cancer.
Based on that the tricyclohexyl tin hydroxide is a substance which is proved to have good biological activity by experiments, and the cyclohexyl has the characteristics of large steric hindrance, large molecular weight and the like, the tricyclohexyl tin hydroxide is selected to react with the ligand 1-naphthoic acid under certain conditions to synthesize the complex with strong inhibitory activity on A549 (human lung cancer cells), Hela (human cervical cancer cells) and HGC-27 (human gastric cancer cells), and a new way is provided for developing anticancer drugs.
Disclosure of Invention
In view of the problems of the prior art, it is a first object of the present invention to provide a tricyclohexyltin 1-naphthoate complex.
It is a second object of the present invention to provide a process for preparing the above tricyclohexyltin 1-naphthoate complex.
The third purpose of the invention is to provide the application of the tricyclohexyl tin 1-naphthoate complex in preparing anti-cancer drugs.
A tricyclohexyltin 1-naphthoate complex as a first aspect of the present invention has the following structural formula (I):
(I)。
the results of the tricyclohexyltin 1-naphthoate complex of the invention after element analysis, infrared spectroscopic analysis and nuclear magnetic resonance spectroscopy are as follows:
elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
The tricyclohexyl tin 1-naphthoate complex has the structural characteristics that: the central tin in the molecule forms a distorted tetrahedral configuration with the coordinating atoms.
In the second aspect of the invention, the preparation method of the tricyclohexyltin 1-naphthoate complex comprises the steps of sequentially adding tricyclohexyltin hydroxide, 1-naphthoic acid and solvent anhydrous methanol into a microwave reaction tank, and carrying out microwave reaction at the radiation power of 800W and the temperature of 100 ℃ for 60-120 min in an air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex.
In a preferred embodiment of the present invention, the ratio of the amounts of the tricyclohexyltin hydroxide and 1-naphthoic acid is 1 (1-1.05).
In a preferred embodiment of the present invention, the solvent anhydrous methanol is used in an amount of 10 to 15 ml per mmol of tricyclohexyltin hydroxide.
The third aspect of the invention relates to the application of tricyclohexyltin 1-naphthoate complex in preparing anticancer drugs.
The applicant carries out in-vitro antitumor activity confirmation research on the complex, and confirms that the complex has certain antitumor biological activity, namely the application of the complex in preparing antitumor drugs, in particular in preparing anti-human lung cancer drugs, human cervical cancer drugs and human gastric cancer drugs.
The tricyclohexyltin 1-naphthoate complex shows good anticancer activity on human lung cancer cells, human cervical cancer cells, human gastric cancer cells and the like, and can be used as a raw material for preparing anti-lung cancer, anti-cervical cancer and anti-gastric cancer drugs. Compared with the platinum anticancer drugs commonly used at present, the tricyclohexyltin 1-naphthoate complex has the characteristics of high anticancer activity, low cost, simple preparation method and the like, and provides a new way for developing anticancer drugs.
Drawings
FIG. 1 is an IR spectrum of a tricyclohexyltin 1-naphthoate complex.
FIG. 2 is a diagram of a tricyclohexyltin 1-naphthoate complex1H NMR spectrumFigure (a).
FIG. 3 is a diagram of a tricyclohexyltin 1-naphthoate complex13C NMR spectrum.
FIG. 4 is a diagram of a tricyclohexyltin 1-naphthoate complex119Sn NMR spectrum.
Detailed Description
The present invention is further illustrated in detail by the following examples, but it should be noted that the scope of the present invention is not limited by these examples at all.
Example 1:
preparation of tricyclohexyltin 1-naphthoate complex:
0.3851 g (1 mmol) of tricyclohexyl tin hydroxide, 0.1722 g (1 mmol) of 1-naphthoic acid and 10 mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 60 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 82%, melting point: 87-89 ℃.
Elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr,v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Example 2:
preparation of tricyclohexyltin 1-naphthoate complex:
0.3854 g (1.0 mmol) of tricyclohexyl tin hydroxide, 0.1806 g (1.05 mmol) of 1-naphthoic acid and 15 mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 60 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 79%, melting point: 87-89 ℃.
Elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Example 3:
preparation of tricyclohexyltin 1-naphthoate complex:
0.3857 g (1 mmol) of tricyclohexyl tin hydroxide, 0.1725 g (1 mmol) of 1-naphthoic acid and 12 mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 120 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 81%, melting point: 87-89 ℃.
Elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Example 4:
preparation of tricyclohexyltin 1-naphthoate complex:
0.7709 g (2.0 mmol) of tricyclohexyl tin hydroxide, 0.3442 g (2 mmol) of 1-naphthoic acid and 25mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 60 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 80%, melting point: 87-89 ℃.
Elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Example 5:
preparation of tricyclohexyltin 1-naphthoate complex:
0.7702 g (2.0 mmol) of tricyclohexyl tin hydroxide, 0.3527 g (2.05 mmol) of 1-naphthoic acid and 25mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 90 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 78%, melting point: 87-89 ℃.
Elemental analysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Example 6:
preparation of tricyclohexyltin 1-naphthoate complex:
1.1554 g (3.0 mmol) of tricyclohexyl tin hydroxide, 0.5163 g (3 mmol) of 1-naphthoic acid and 30 mL of solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out at the radiation power of 800W and the temperature of 100 ℃ for 120 min under the air atmosphere. After the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex. Yield: 80%, melting point: 87-89 ℃.
Element classificationAnalysis (C)29H40O2Sn): theoretical value: c, 64.58; h, 7.48. Measurement value: c, 64.52; h, 7.45.
IR (KBr, v/cm-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19(w), 1624.06 (s), 1602.85 (s), 1562.34 (s), 1508.33 (w), 1469.76 (m) 1446.61(w), 1382.96 (s), 1346.31 (w), 1280.73 (s), 1255.66 (s), 1207.44 (w), 1170.79(m), 1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w)。
1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J=10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J= 8 Hz, 1H),7.60(d,J= 8 Hz,1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m,9H)。
13C NMR (CDCl3, 125 MHz)δ(ppm): 172.91, 133.95, 132.17, 131.67,130.35, 129.96, 128.31, 127.09, 126.70,125.76, 124.66, 34.06, 31.24, 29.00,26.97。
119Sn NMR (CDCl3, 186 MHz), δ (ppm): 16.70。
Test example:
the determination of the in vitro anticancer activity of the tricyclohexyl tin 1-naphthoate complex is realized by an MTT experimental method.
MTT assay:
based on the metabolic reduction of 3- (4, 5-dimethylthiozol-2-yl) -2, 5-diaryltetrazolium bromide. Succinate dehydrogenase in mitochondria of living cells can reduce exogenous MTT to water-insoluble blue-purple crystalline Formazan (Formazan) and deposit in cells, while dead cells do not have this function. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and the optical density of characteristic wavelength is measured by enzyme labeling instrument, which can indirectly reflect the number of living cells.
MTT method was used to measure the inhibitory activity of the tricyclohexyltin 1-naphthoate complex prepared in example 1 on human lung cancer cells (A549), human cervical cancer cells (Hela), and human gastric cancer cells (HGC-27).
Cell line and culture System: the A549, Hela and HGC-27 cell lines were obtained from the American tissue culture Bank (ATCC). Using RPMI1640 medium (GIBICO) containing 10% fetal bovine serum at 5% (volume fraction) CO2And culturing in vitro in a 37 ℃ saturated humidity incubator.
The testing process comprises the following steps: and respectively adding the test liquid medicine (0.0625-0.5 mu mol/L) into each hole according to the concentration gradient of the concentration, wherein each concentration is provided with 3 parallel holes. The experiment was divided into drug test group (with different concentrations of test drug added), control group (with culture medium and cells only, without test drug added) and blank group (with culture medium only, without cells and test drug added). Placing the medicated hole plate at 37 deg.C and 5% CO2Culturing in an incubator for 24 h. The activity of the control drug was determined as per the method of the test sample. In the well plate after 48 hours of incubation, 20uL of MTT (5 g/L in PBS) was added to each well. After standing at 37 ℃ for 4h, the supernatant was removed. Add 150uL DMSO to each well, shake for 10min to dissolve the Formazan crystals. Finally, the absorbance of each well was measured at a wavelength of 570nm using a BioTek multifunctional microplate reader.
Data processing: data processing Using GraAr Pad Prism version5.0 program, Complex IC50Fitting was done by a non-linear regression model with sigmoidal dose response in the program.
Analyzing human lung cancer cell (A549) cell line, human cervical cancer cell (Hela) cell line and human gastric cancer cell (HGC-27) cell line by MTT analysis method, and determining IC50The results are shown in table 1, with the conclusion that: as can be seen from the data in the table, the tricyclohexyltin 1-naphthoate complex has high anticancer activity on human lung cancer, human cervical cancer and human gastric cancer as an anticancer drug, and can be used as a candidate complex of the anticancer drug.
Table 1 tricyclohexyltin 1-naphthoate complex anticancer drug in vitro activity test data.
| Human lung cancer cell | Human cervical cancer cell | Human gastric cancer cell | |
| Cell line | A549 | Hela | HGC-27 |
| IC50μM | 0.4044 | 0.6749 | 0.1359 |
The tricyclohexyltin 1-naphthoate complexes prepared in the other examples were tested for anticancer activities against human lung cancer cells (a 549), human cervical cancer cells (Hela) and human gastric cancer cells (HGC-27) by MTT method in the same experimental examples, and the test results were substantially the same as in table 1.
Claims (7)
1. A tricyclohexyltin 1-naphthoate complex, which is a complex of the following structural formula (I):
(I)。
2. the tricyclohexyltin 1-naphthoate complex of claim 1 having an infrared spectrum of: FT-IR (KBr, v/cm)-1): : 3049.46 (w), 2920.23 (s), 2845.00 (s), 2650.19 (w),1624.06 (s)1602.85(s), 1562.34(s), 1508.33 (w), 1469.76 (m) 1446.61 (w), 1382.96(s), 1346.31 (w), 1280.73(s), 1255.66(s), 1207.44 (w), 1170.79 (m),1083.99 (w), 1035.77 (w), 991.41 (m), 964.41(w), 875.68 (w), 821.68 (m),796.60 (w), 740.67 (m), 651.94 (m), 601.79 (m), 532.35 (w), 495.71 (m),478.35 (w), 418.55 (w); nuclear magnetic spectrum data thereof:1H NMR (CDCl3, 500 MHz)δ(ppm): 9.00 (d,J= 8.5 Hz, 1H), 8.23(d,J= 10 Hz, 1H), 7.96(d,J= 7.5 Hz, 1H), 7.87(d,J=8 Hz, 1H),7.60(d,J= 8 Hz, 1H), 7.52-7.47 (m, 2H), 2.08-1.99 (m, 9H), 1.86-1.58 (m, 15H), 1.44-1.38 (m, 9H);13C NMR(CDCl3, 125 MHz)δ(ppm): 172.91,133.95, 132.17, 131.67, 130.35, 129.96, 128.31, 127.09, 126.70,125.76,124.66, 34.06, 31.24, 29.00, 26.97;119Sn NMR (CDCl3, 186 MHz), δ (ppm):16.70。
3. the preparation method of tricyclohexyltin 1-naphthoate complex as claimed in claim 1, characterized in that tricyclohexyltin hydroxide, 1-naphthoic acid and solvent anhydrous methanol are sequentially added into a microwave reaction tank in order, and microwave reaction is carried out under air atmosphere at a radiation power of 800W and a temperature of 100 ℃ for a duration of 60-120 min; after the reaction is finished, naturally cooling, filtering, and naturally volatilizing and crystallizing the solvent at room temperature to obtain a golden crystal, namely the tricyclohexyltin 1-naphthoate complex.
4. The method according to claim 3, wherein the ratio of the amounts of tricyclohexyltin hydroxide and 1-naphthoic acid is 1 (1 to 1.05).
5. The method according to claim 3, wherein the solvent is 10 to 15 ml of anhydrous methanol per mmol of tricyclohexyltin hydroxide.
6. Use of the tricyclohexyltin 1-naphthoate complex of claim 1 in the preparation of an anti-cancer medicament.
7. The use of claim 7, wherein the cancer cell is lung cancer, cervical cancer, gastric cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911369692.6A CN111138487B (en) | 2019-12-26 | 2019-12-26 | Preparation method and application of tricyclohexyltin 1-naphthoate complex |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911369692.6A CN111138487B (en) | 2019-12-26 | 2019-12-26 | Preparation method and application of tricyclohexyltin 1-naphthoate complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111138487A true CN111138487A (en) | 2020-05-12 |
| CN111138487B CN111138487B (en) | 2023-10-24 |
Family
ID=70520600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911369692.6A Active CN111138487B (en) | 2019-12-26 | 2019-12-26 | Preparation method and application of tricyclohexyltin 1-naphthoate complex |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111138487B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188128A (en) * | 2016-07-15 | 2016-12-07 | 衡阳师范学院 | A kind of Tricyclohexyltin 2 naphthoate coordination compound and preparation method and application |
| CN110128466A (en) * | 2019-05-31 | 2019-08-16 | 衡阳师范学院 | Three (2- methyl -2- phenyl) propyl tin 3- indolebutyric acid ester complexs of one kind and preparation method and application |
-
2019
- 2019-12-26 CN CN201911369692.6A patent/CN111138487B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188128A (en) * | 2016-07-15 | 2016-12-07 | 衡阳师范学院 | A kind of Tricyclohexyltin 2 naphthoate coordination compound and preparation method and application |
| CN110128466A (en) * | 2019-05-31 | 2019-08-16 | 衡阳师范学院 | Three (2- methyl -2- phenyl) propyl tin 3- indolebutyric acid ester complexs of one kind and preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111138487B (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111057097B (en) | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] 3-nitrophthalate complex | |
| CN111153929A (en) | Preparation method and application of tricyclohexyltin 4-chlorobenzoate complex | |
| CN111138488A (en) | Preparation method and application of bis [ tri (2-methyl-2-phenylpropyl) ] tin isophthalate complex | |
| CN111138484A (en) | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyl tin ] fumarate complex | |
| CN111138480B (en) | Preparation method and application of tricyclohexyltin quinoline-4-formate complex | |
| CN111138487A (en) | Preparation method and application of tricyclohexyltin 1-naphthoate complex | |
| CN111057092A (en) | Tris (2-methyl-2-phenylpropyl) tin 3-aminopiperazine acid ester complex, preparation method and application thereof | |
| CN111116638A (en) | Tricyclohexyltin 3-methylthiophene-2-formate complex, and preparation method and application thereof | |
| CN111138485B (en) | Preparation method and application of tricyclohexyl tin cinnamate complex | |
| CN111057096A (en) | Preparation method and application of tri (2-methyl-2-phenylpropyl) tin m-methyl benzoate complex | |
| CN111138486A (en) | Preparation method and application of tris (2-methyl-2-phenylpropyl) stannoic acid ester complex | |
| CN111087419A (en) | Preparation method and application of tri (2-methyl-2-phenylpropyl) tin p-chlorobenzoate complex | |
| CN111116639A (en) | Preparation method and application of tris (2-methyl-2-phenylpropyl) tin 3, 5-dimethoxy benzoate complex | |
| CN111704631A (en) | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] pamoate complex | |
| CN111153928A (en) | Preparation method and application of tri (2-methyl-2-phenylpropyl) tin 2-naphthoate complex | |
| CN111138477B (en) | Preparation method and application of tricyclohexyltin quinoline-6-formate complex | |
| CN111116640A (en) | Preparation method and application of tri (2-methyl-2-phenylpropyl) tin indole-6-formate complex | |
| CN111217851A (en) | Preparation method and application of tricyclohexyltin indole-4-formate complex | |
| CN111057098A (en) | Preparation method and application of tri (2-methyl-2 phenylpropyl) tin 1-naphthoate complex | |
| CN111217852A (en) | Preparation method and application of tri (2-methyl-2-phenylpropyl) tin p-methylbenzoate complex | |
| CN111116636A (en) | Preparation method and application of tricyclohexyltin indole-6-formate complex | |
| CN111138481A (en) | Preparation method and application of tricyclohexyltin indole-3-formate complex | |
| CN111057091A (en) | Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] 5-aminoisophthalate complex | |
| CN106279255B (en) | Bis (tributyltin) fumarate complex and preparation method and application thereof | |
| CN111138482A (en) | Tris (2-methyl-2-phenyl propyl) tin 5-bromo-2-furoate complex and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |